Fluidigm Corporation has announced that they will provide a status update on its ground-breaking Stem Cell Chip at the World Stem Cell Summit in Baltimore, Maryland, USA (September 21st – 23rd 2009).

The chip is expected to be available to the market next year. Fluidigm’s CEO Gajus Worthington and CSO Marc Unger will be at the conference and available to meet with the press and answer questions. Press meetings may be booked in advance by contacting howard.high@fluidigm.com.

The World Stem Cell Summit (https://www.worldstemcellsummit.com/) will bring together the stem cell universe of researchers, ReGEN industry leaders, funders, medical philanthropies, policy-makers, advocates, educators and regulators to chart the future of regenerative medicine. The comprehensive, multi-track program will cover advanced science, commercial perspectives, disease progress reports and in-depth reviews of policy, law, ethics, regulatory issues and global economic development.

At this prestigious event a number of prominent stem cell researchers using Fluidigm equipment including Dr. Irving Weissman, Institute for Stem Cell Biology & Regenerative Medicine (Stanford University, USA) and Dr. Toshio Suda, Graduate School of Medicine (Keio University, Japan) will be giving presentations on their research.

Historically, gene expression profiling of single cells, such as stem cells, has been difficult and expensive to perform. Now, however, results from single-cell samples can be obtained easily and inexpensively using the Fluidigm’s BioMark™ System and the company’s Dynamic Array™ integrated fluidic circuits (IFCs). Dynamic Array IFCs are ideally suited for high-throughput cell-line studies to determine individual cell behaviour in a homozygous population.

A presentation describing this technology in more detail may be viewed at https://www.fluidigm.com/pdf/presentations/FLDM_Livak_qPCR_USA_Nov_11_08.pdf.

Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science research. Fluidigm’s IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These “integrated circuits for biology” are made possible by miniaturizing and integrating liquid handling components on a single microfabricated microfluidic device. Fluidigm’s IFC systems, consisting of instrumentation, software and single-use IFCs, increase throughput, decrease costs and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the Food and Drug Administration for use as a diagnostic and are only available for research use.

* Fluidigm, the Fluidigm logo, BioMark, Dynamic Array, Digital Array, Access Array and NanoFlex are trademarks of Fluidigm Corporation and all other trademarks are the property of their respective owners.